Editor’s note: This is an automatically generated transcript. Please notify editor@healio.com if there are concerns regarding accuracy of the transcription. In general, the most common type of ...
"Omega -3 fatty acids are essential nutrients often missing in modern diets. While much attention is given to protein , Vitamin D, and iron , omega -3 deficiency remains an under-recognized concern ...
MINNEAPOLIS — Severe nutritional deficiencies can mimic rheumatic disease and result in delayed diagnosis and unnecessary workups, as illustrated in a series of four cases presented at the American ...
The NFL offseason continues to trudge along as free agency has made it through its first week, and the Green Bay Packers have been able to add to their roster, as they typically have done under Brian ...
Dilated cardiomyopathy (DCM) is the leading cause of heart failure with a poor prognosis. Recent studies suggest that endothelial to mesenchymal transition (EndMT) may be involved in the pathogenesis ...
In a phase 3 trial, oral ferric citrate effectively raised hemoglobin and improved iron parameters in Taiwanese patients with iron deficiency anemia over 16 weeks. Ferric citrate significantly ...
A comprehensive Vue 3 Calendar component with Vuetify 3, TypeScript, and advanced features including drag & drop, lazy loading, filtering, and multiple view modes. The following code snippets show a ...
Our results show that HAS3 plays a key role in AAA/AD formation and suggest the HAS3/CD44 axis as promising therapeutic target to reduce monocyte recruitment and aortic rupture. Since inflammation and ...
While most muscle cramps occur due to idiopathic (unknown) causes, they are often linked with factors such as exercise, muscle overuse, straining, and diet. Muscle cramps can also occur in people with ...
BridgeBio Pharma is having a banner week, with the Bay Area company’s encaleret acing a phase 3 trial just days after another late-stage rare disease win as its eyes an FDA review in 2026. In the ...
Novo Nordisk is paying $240 million for global rights to a Phase 3-ready drug from Omeros that could rival immune disorder medications currently available from companies such as AstraZeneca, Novartis, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results